IntriCon Corporation (IIN) News
Filter IIN News Items
IIN News Results
|Loading, please wait...|
IIN News Highlights
- For IIN, its 30 day story count is now at 4.
- Over the past 16 days, the trend for IIN's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- ID, STEP and TTDKY are the most mentioned tickers in articles about IIN.
Latest IIN News From Around the Web
Below are the latest news stories about Intricon Corp that investors may wish to consider to help them evaluate IIN as an investment opportunity.
IntriCon Corporation (IIN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
IntriCon Corporation (IIN) Q1 2021 Results Conference Call May 10, 2021 05:00 PM ET Company Participants Leigh Salvo - Investor Relations Scott Longval - Chief Executive Officer Ellen Scipta - Chief Financial Officer Conference Call Participants Andrew D'Silva - B. Riley Securities Jon Block - Stifel Kyle Bauser - Collier...
ARDEN HILLS, Minn., April 26, 2021 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ: IIN), an international company engaged in designing, developing, engineering and manufacturing miniature interventional, implantable and body-worn medical devices, today announced that it will release its 2021 first quarter results on Monday, May 10, 2021, after market close. Following the release, Intricon’s management team will host a conference call on the same day, beginning at 4:00 p.m. CT/5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing (866) 795-7248 for domestic callers or (470) 495-9160 for international callers, using conference ID: 9769435. A live and archived webcast will be available on the “Investors” sections of the company’s website at: www.intr...
TTDKY vs. IIN: Which Stock Is the Better Value Option?
ARDEN HILLS, Minn., March 22, 2021 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ: IIN), an international company engaged in designing, developing, engineering, and manufacturing miniature interventional, implantable and body-worn medical devices, today announced the appointment of Kathleen Pepski to the company’s Board of Directors, effective March 19, 2021. “We are delighted to welcome Kathleen to Intricon and our board of directors,” said Scott Longval, President and Chief Executive Officer of Intricon. “Kathleen is a well-respected business leader in Minneapolis whose background in manufacturing and distribution, as well as mergers and acquisitions, will be instrumental in our long-term growth strategy.” Ms. Pepski’s career includes more than 30 years of finance and accounting exp...
Europe Ear-Based Hearing Aids Market 2028 Competitions by Players, Present Situation Analysis, Development, Challenges | GN Store Nord A/S, IntriCon Corporation, MED-EL, Sivantos Pte. Ltd., Sonova, Starkey, Knowles Electronics
Allied Market Research (USA, Oregon, Portland) Published Latest Report titled, ‘Europe Ear-Based Hearing Aids Market : Global Opportunity Analysis and Industry Forecast 2021-2028’. The Europe Ear-Based Hearing Aids Market is expected to witness growth in upcoming years due to factors such
Shares of IntriCon (NASDAQ:IIN) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 50.00% year over year to $0.12, which beat the estimate of $0.04. Revenue of $30,301,000 rose by 9.41% year over year, which beat the estimate of $27,350,000. Outlook Earnings guidance hasn't been issued by the company for now. Revenue guidance hasn't been issued by the company for now. How To Listen To The Conference Call Date: Feb 25, 2021 View more earnings on IIN Time: 05:00 PM ET Webcast URL: https://edge.media-server.com/mmc/p/y6bpms6j Technicals 52-week high: $23.18 52-week low: $9.84 Price action over last quarter: Up 45.46% Company Description IntriCon Corp design, develop and manufacture miniature and micro-miniature body-worn medic...
ARDEN HILLS, Minn., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ: IIN), an international company engaged in designing, developing, engineering, and manufacturing miniature interventional, implantable and body-worn medical devices, today announced financial results for its fourth quarter and year ended December 31, 2020. Fourth Quarter Highlights: Revenue of $30.3 million compared to $27.7 million in the prior year period Diabetes revenue was flat compared to the prior year periodOther medical revenue increased 74.3% over the prior year period, which included the contribution from Emerald Medical Services (“EMS”) acquired in May 2020 Gross margin of 25.7%, compared to 26.9% in the prior year periodNet income of $0.12 per diluted share versus net income of $0.08 per dilu...
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors’ consensus returns have been exceptional. In the following paragraphs, we find out […]